Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene
Public ClinicalTrials.gov record NCT00847821. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
RNA Expression Analysis Of Endometrial Biopsies Comparing Placebo, Bazedoxifene/ Conjugated Estrogens And Raloxifene
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is an observational study analyzing the biopsy samples collected from subjects that participated in Study 3115A1-303 (NCT00675688). These endometrial biopsy samples will be de-identified at an anatomical laboratory and then sent to a molecular biology lab where an RNA extraction and analysis will be performed. The purpose of this study is to compare specific endometrial gene regulation at the level of mRNA expression in samples from placebo, bazedoxifene/conjugated estrogens, and raloxifene treated groups with a known set of genes that have been previously identified to be associated with estrogenization, endometrial hyperplasia, and endometrial cancer.
Study identification
- NCT ID
- NCT00847821
- Recruitment status
- Terminated
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 185 participants
Conditions and interventions
Conditions
Interventions
- Bazedoxifene 10 mg/CE 0.625 mg Drug
- Bazedoxifene 20 mg/CE 0.625 mg Drug
- Bazedoxifene 40 mg/CE 0.625 mg Drug
- Bazedoxifene 10 mg/CE 0.45 mg Drug
- Bazedoxifene 20 mg/CE 0.45 mg Drug
- Bazedoxifene 40 mg/CE 0.45 mg Drug
- Raloxifene 60 mg Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 75 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2009 (Type not available)
- Primary completion
- Aug 2010 (Actual)
- Completion
- Aug 2010 (Actual)
- Last update posted
- Sep 6, 2010
2009 – 2010
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Fort Myers | Florida | 33916 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32606 | — |
| Pfizer Investigational Site | New Port Richey | Florida | 34652 | — |
| Pfizer Investigational Site | West Palm Beach | Florida | 33409 | — |
| Pfizer Investigational Site | Decatur | Georgia | 30033 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60610 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40536 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40291 | — |
| Pfizer Investigational Site | Southfield | Michigan | 48034 | — |
| Pfizer Investigational Site | Chaska | Minnesota | 55318 | — |
| Pfizer Investigational Site | Billings | Montana | 59102 | — |
| Pfizer Investigational Site | New Brunswick | New Jersey | 08901 | — |
| Pfizer Investigational Site | Las Vegas | New Mexico | 89416 | — |
| Pfizer Investigational Site | Rochester | New York | 14642 | — |
| Pfizer Investigational Site | Raleigh | North Carolina | 27609 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45267 | — |
| Pfizer Investigational Site | Wexford | Pennsylvania | 15090 | — |
| Pfizer Investigational Site | Greenville | South Carolina | 29605 | — |
| Pfizer Investigational Site | Dallas | Texas | 75390 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | Charlottesville | Virginia | 22903 | — |
| Pfizer Investigational Site | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00847821, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 6, 2010 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00847821 live on ClinicalTrials.gov.